Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial

  1. Camus, V.
  2. Thieblemont, C.
  3. Gaulard, P.
  4. Cheminant, M.
  5. Casasnovas, R.-O.
  6. Ysebaert, L.
  7. Damaj, G.L.
  8. Guidez, S.
  9. Pica, G.M.
  10. Kim, W.S.
  11. Lim, S.T.
  12. Andre, M.
  13. Gutiérrez, N.
  14. Penarrubia, M.J.
  15. Staber, P.B.
  16. Trotman, J.
  17. Hüttmann, A.
  18. Stefoni, V.
  19. Tucci, A.
  20. Fogarty, P.
  21. Farhat, H.
  22. Abraham, J.
  23. Abarah, W.
  24. Belmecheri, F.
  25. Ribrag, V.
  26. Delfau-Larue, M.-H.
  27. Cottereau, A.-S.
  28. Itti, E.
  29. Li, J.
  30. Delarue, R.
  31. de Leval, L.
  32. Morschhauser, F.
  33. Bachy, E.
  34. Show all authors +
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

ISSN: 1527-7755

Year of publication: 2024

Volume: 42

Issue: 14

Pages: 1612-1618

Type: Article

DOI: 10.1200/JCO.23.01687 GOOGLE SCHOLAR

Sustainable development goals